Contribute Try STAT+ Today

There’s a rapidly expanding market for new DNA tests aimed at helping seemingly healthy people gain insights into their risk of developing all sorts of diseases.

The latest entrant, launched on Tuesday, promises to analyze a canonical list of 59 genes that influence your likelihood of developing certain cancers and heart problems, along with other conditions. The new GenePrism test comes from PerkinElmer, a Massachusetts diagnostics company, and Helix, a Silicon Valley startup that’s developed something of an app store for DNA tests.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.